Re: Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate- and High-Risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-Third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG
Since the first report on the use of intravesical BCG in 1976 the optimal dose and duration of treatment is controversial. The main concern on defining the optimal BCG dose is to have fewer side effects while keeping anti-tumor efficacy. Efficacy of 1/3 dose (1/3D) vs. full dose (FD) BCGwas previou...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2015-03-01
|
| Series: | Journal of Urological Surgery |
| Online Access: | http://jurolsurgery.org/article_8789/Re-Dissecting-The-Association-Between-Metabolic-Syndrome-And-Prostate-Cancer-Risk-Analysis-Of-A-Large-Clinical-Cohort |